Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer by Stick, Line B et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal
Photon Versus Proton Therapy for Breast Cancer
Stick, Line B; Yu, Jen; Maraldo, Maja V; Aznar, Marianne C; Pedersen, Anders N; Bentzen,
Søren M; Vogelius, Ivan R
Published in:
International Journal of Radiation Oncology, Biology, Physics
DOI:
10.1016/j.ijrobp.2016.12.008
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Stick, L. B., Yu, J., Maraldo, M. V., Aznar, M. C., Pedersen, A. N., Bentzen, S. M., & Vogelius, I. R. (2017). Joint
Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton
Therapy for Breast Cancer. International Journal of Radiation Oncology, Biology, Physics, 97(4), 754-761.
https://doi.org/10.1016/j.ijrobp.2016.12.008
Download date: 03. Feb. 2020
International Journal of
Radiation Oncology
biology physics
www.redjournal.orgClinical InvestigationJoint Estimation of Cardiac Toxicity and
Recurrence Risks After Comprehensive Nodal
Photon Versus Proton Therapy for Breast Cancer
Line B. Stick, MSc,*,y Jen Yu, PhD,z Maja V. Maraldo, MD, PhD,*
Marianne C. Aznar, PhD,*,x Anders N. Pedersen, MD, PhD,*
Søren M. Bentzen, PhD, DMSc,*,z,k and Ivan R. Vogelius, PhD*
*Department of Clinical Oncology, Rigshospitalet, and yNiels Bohr Institute, Faculty of Science,
University of Copenhagen, Copenhagen, Denmark; zMaryland Proton Treatment Center, and
kGreenebaum Comprehensive Cancer Center and Department of Epidemiology and Public Health,
University of Maryland School of Medicine, Baltimore, Maryland; and xNuffield Department of
Population Health, University of Oxford, Oxford, UKReceived Sep 22, 2016, and in revised form Nov 22, 2016. Accepted for publication Dec 2, 2016.Summary
Evidence-based bioeffect
models were used to provide
patient-level risk estimates
for clinically delivered
photon therapy plans
compared with proton ther-
apy plans in 41 consecutive
patients with left-sided
breast cancer referred for
comprehensive nodal irradi-
ation. The joint estimation of
risk of recurrence caused by
target dose compromises and
risk of cardiac morbidityReprint requests to: Line B. Stick, MSc, Rigs
2100 Copenhagen, Denmark. Tel: 0045
.bjerregaard.stick@regionh.dk
This study was supported by Danish Can
A7989-15-S37, Kirsten and Freddy Johans
Research UK grant C8225/A21133, and Nationa
P30 CA 134274-04.
Conflict of interest: I.R.V. and M.C.A. rece
fees from Varian Medical Systems.
Int J Radiation Oncol Biol Phys, Vol. 97, No. 4
0360-3016/$ - see front matter  2016 Publish
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by inadequate radiation dose coverage of lymph node targets and the risk of cardiac
toxicity caused by radiation exposure to the heart. Delivered photon plans are
compared with realistic proton plans, thereby providing evidence-based estimates of
the heterogeneity of treatment effects in consecutive cases for the 2 radiation treatment
modalities.
Methods and Materials: Forty-one patients referred for postlumpectomy comprehen-
sive nodal photon irradiation for left-sided breast cancer were included. Comparative
proton plans were optimized by a spot scanning technique with single-field optimiza-
tion from 2 en face beams. Cardiotoxicity risk was estimated with the model of Darby
et al, and risk of recurrence following a compromise of lymph node coverage was esti-
mated by a linear dose-response model fitted to the recurrence data from the recently
published EORTC (European Organisation for Research and Treatment of Cancer)
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Group) MA.20 randomized controlled trials.hospitalet, Blegdamsvej 9,
35451518; E-mail: line
cer Society grant R125-
en’s Foundation, Cancer
l Institutes of Health grant
ive grants and educational
Supplementary material for this article can be found at
www.redjournal.org.
AcknowledgmentsdThe authors acknowledge Birgitte Offersen and
Lise Thorsen for supplying reanalysis of the Danish Breast Cancer
Cooperative Group Internal Mammary Node study with the endpoint of
disease-free survival for sensitivity analysis of our model with respect to
using data from the randomized studies versus the Danish Breast Cancer
Cooperative Group study.
, pp. 754e761, 2017
ed by Elsevier Inc.
Volume 97  Number 4  2017 Cardiac toxicity and recurrence risks after breast cancer 755differed markedly between
patients and radiation treat-
ment modalities.Results: Excess absolute risk of cardiac morbidity was small with photon therapy at
an attained age of 80 years, with median values of 1.0% (range, 0.2%-2.9%) and 0.5%
(range, 0.03%-1.0%) with and without cardiac risk factors, respectively, but even
lower with proton therapy (0.13% [range, 0.02%-0.5%] and 0.06% [range, 0.004%-
0.3%], respectively). The median estimated excess absolute risk of breast cancer recur-
rence after 10 years was 0.10% (range, 0.0%-0.9%) with photons and 0.02% (range,
0.0%-0.07%) with protons. The association between age of the patient and benefit
from proton therapy was weak, almost non-existing (Spearman rank correlations of
0.15 and 0.30 with and without cardiac risk factors, respectively).
Conclusions: Modern photon therapy yields limited risk of cardiac toxicity in most
patients, but proton therapy can reduce the predicted risk of cardiac toxicity by up
to 2.9% and the risk of breast cancer recurrence by 0.9% in individual patients. Pre-
dicted benefit correlates weakly with age. Combined assessment of the risk from car-
diac exposure and inadequate target coverage is desirable for rational consideration of
competing photon and proton therapy plans.  2016 Published by Elsevier Inc.Introduction
Recent randomized controlled trials have demonstrated a
clinically relevant benefit of lymph node irradiation in
breast cancer patients with certain adverse factors (1, 2),
consistent with nonrandomized evidence from a
population-based study (3). Irradiation of the internal
mammary nodes (IMNs) in left-sided breast cancer patients
will, however, inevitably increase the radiation exposure to
the cardiac structures, which has been shown to increase the
risk of cardiac morbidity and death (4). Current practice
most often compromises target coverage if necessary to
adhere to cardiac dose constraints defined in treatment
guidelines. The application of advanced photon therapy
techniques can improve the target coverage-cardiac dose
balance (5-7) as compared with historical techniques, but
compromises are still inevitable. In this study, joint radio-
biological modeling of cardiotoxicity and tumor recurrence
risks is applied to quantify the patient-specific risk esti-
mation. Clinically delivered photon dose plans are
compared with proton plans to estimate the patient-level
outcomes after the 2 radiation treatment modalities.
The marked heterogeneity in cardiac exposure in pa-
tients undergoing comprehensive breast cancer irradiation
is a consequence of anatomic differences. This study
included all 41 patients referred to our standard protocol for
left-sided postlumpectomy radiation therapy with compre-
hensive nodal irradiation in 2015. This approach allows
assessment of the variation in potential patient benefit from
referral to proton therapy.Methods and Materials
Forty-one patients referred to Rigshospitalet during 2015
for unilateral left-sided postlumpectomy locoregional ra-
diation therapy including the ipsilateral IMN chain were
included in the study. The planning computed tomography
(CT) scan from the clinically delivered photon therapy wasused for developing a competing proton beam spot scan-
ning plan. All patients were scanned in the supine position
with the deep inspiration breath-hold (DIBH) technique
according to department guidelines (8).
Original target structure delineations for the delivered
photon plans were used in this study: The whole breast with
retraction from the skin of 5 mm and lymph nodes (IMN,
level II axillary, level III axillary, level IV, and interpec-
toral) were delineated as clinical target volumes (CTVs)
according to guidelines from the European Society for
Radiotherapy and Oncology (ESTRO) (9). Level I was
irradiated in 1 patient and dissected in all others.
The heart had generally not been delineated for the
delivered plans (with few exceptions) following the 2015
standard procedure at Rigshospitalet, which limited dose to
the left anterior descending coronary artery (LADCA) as a
dose metric related to cardiac risk. Thus the whole heart
was contoured or recontoured retrospectively for the pur-
pose of this study following published guidelines (10). All
other contours were delineated by the treating physician at
the time of treatment (ie, multiple observers).
The prescribed dose was 50 Gy in 25 fractions for all
patients. For patients younger than 50 years, a boost was
delivered, but this was not considered for the purpose of
this study (contributioned <0.2 Gy to mean heart dose
[MHD] for all patients).
Photon planning
Thirty-nine patients were treated with 3-dimensional (3D)
conformal radiation therapy (CRT) comprising 2 main
tangential opposing breast fields and a supraclavicular field
(or fields) with the beam junction at the isocenter and 6 to
11 forward planned supplementary fields (examples of
beam configurations are shown in Fig. A1; available online
at www.redjournal.org). Six megavolts was used for most
fields, sometimes supplemented by 18 megavolts to reach
deep-seated targets or reduce hot spots. Planning target
volumes (PTVs) were not used for the 3D CRT plans;
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applied above the isocenter. When target coverage com-
promises were required, CTV delineation was not modified;
instead, a help structure was defined or a controlled
compromise on CTV coverage was performed.
The remaining 2 patients were treated with hybrid plans:
volumetric modulated arc therapy combined with 3D CRT
(11). Both these patients had the heart delineated and
prioritized in addition to the LADCA. A volumetric
modulated arc therapy-specific PTV was created for opti-
mization by a 5 to 6 mm expansion of the CTV and con-
tracted to 3 to 4 mm below the skin surface. Eclipse,
version 13.0 (Varian Medical Systems), with the AAA al-
gorithm (29 patients) or the AcurosXB algorithm (12 pa-
tients), was used for dose calculation.
Four patients underwent rescanning or replanning during
the radiation therapy course. For these cases, the plan used
for the majority of fractions was chosen as the photon
reference for the comparison.
Clinical planning objectives were to cover the whole
breast CTV by between 95% and 107% of the prescribed
dose and the lymph node CTVs with 90% to 107% of the
dose. The maximum dose to the LADCAwas <20 Gy, and
the left lung V20Gy (ie, volume that receives 20 Gy) was
35%. No part of the body should receive >110% of the
prescription dose.Proton planning
Proton plans were optimized in Eclipse, version 13.6, and
the plans were approved as suitable for clinical treatment
delivery by the physicians and physicists. A proton beam-
specific PTV was created for optimization. The breast PTV
was created with a lateral margin of 5 mm to account for
setup errors, as well as a distal margin of 2 to 4 mm to
account for range uncertainties, and it excluded the chest
wall, ribs, and intercostal muscle posteriorly and 3 to 4 mm
of skin anteriorly. The lymph node PTV was created with a
5 mm isotropic margin without any contractions. Special
PTVs with a distal margin of 10 mm were created for 2
patients with breast implants (the implants were not a part
of the breast CTVs). The proton plans were planned on a
nonclinical system but assuming the monitor units to be
defined as relative biological effectiveness-corrected doses
(ie, 1.1  physical dose).
Two en face beams were used: one field with angles in
the range from 5 to 10 and the other in the range from 50
to 60 (Fig. A1; available online at www.redjournal.org).
Plans were optimized with single-field optimization in
which each beam is optimized independently to cover the
target uniformly to 50% of the prescribed dose. A range
shifter of water-equivalent thickness of 57 mm was applied.
The spot spacing was fixed at 0.5 mm. The proton plans
were normalized to a mean total CTV dose of 50 Gy.
In 3 cases the CT scans included air cavities. The density of
the air cavities was assigned to be water by overriding theHounsfield units for planning purposes to ensure adequate
proton energy to deliver the prescribed dose in case the air
cavities were filledwith fluid. The planning objectiveswere to
cover the total CTV by between 95% and 107% of the pre-
scribed dosewhile dose to heart, LADCA, and lung should be
as low as reasonably achievable.
Robustness analysis
Uncertainties in patient setup and proton beam range were
estimated by the integrated plan robustness tool in Eclipse.
Isocenter shifts were assumed to have a normal distribution
in each fraction, with 1.96  SD Z 5 mm in the x, y,
and z directions and constant calibration errors of
1.96  SD Z 3.5%. Appendix (available online at www.
redjournal.org) presents details of the robustness analysis. A
corresponding robustness analysis of the photon plans toward
setup uncertainties was performed as described in Appendix
(available online at www.redjournal.org).
Plan evaluation and bioeffect modeling
A homogeneity index (HI) (12) was applied to evaluate
CTV coverage: HI Z (D2  D98)/D50, where D2, D50,
and D98 are the doses received by 2%, 50%, and 98% of
the CTV, respectively. A low HI implies homogeneous
coverage.
Table S13 in the appendix of the article by Darby et al
(4) contains excess absolute risk (EAR) estimates of at least
1 acute coronary event (ACE) at age 80 years, where an
ACE was defined as myocardial infarction, coronary
revascularization, angina, or death from ischemic heart
disease. For the purpose of this study, we used bivariate
polynomial interpolation between table values (poly55;
MatLab, The MathWorks) with the MHDs from the photon
or proton plan and the patient’s actual age at the time of
treatment as the input variables; all patient cases were
modeled both with and without pre-existing cardiac risk
factors (CRFs). For 4 patients aged 26, 31, 35, and 36 years,
the model input age was set to 40 years because of the
range of the original tables.
The EAR of breast cancer recurrence 10 years after
treatment as a consequence of target dose compromises was
modeled as follows: Clinical effect size was derived from
the empirical hazard ratio (HR) for disease-free survival
(DFS) from the meta-analysis of the EORTC (European
Organisation for Research and Treatment of Cancer)
22922/10925 and NCIC-CTG (National Cancer Institute of
Canada Clinical Trials Group) MA.20 trials (1, 2). The
meta-analysis yields HR Z 0.86 (13) when adding nodal
irradiation to primary target irradiation. A linear dose-
response model was assumed for the benefit of the pro-
portion of the mean dose to IMN. For example, if the mean
IMN dose was 35 Gy instead of 50 Gy (prescribed dose) in
a given patient, this patient was expected to receive 70% of
the benefit seen in the randomized trials (effective hazard
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sume that the baseline 10-year DFS without regional node
irradiation, p1, was 71.6% (weighted mean of trials) and
calculated the expected DFS for the realized target
coverage, p2 Z p1HReffective. Finally, the EAR was evalu-
ated as the absolute loss comparing with the “ideal” HRZ
0.86: EAR Z p1HR  p1HReffective. Mean IMN doses
>50 Gy were truncated at 50 Gy in the modeling (4 photon
and 3 proton plans).
Results
Patient characteristics are provided in Table 1. An illus-
trative example of the comparative treatment plans is pre-
sented in Figure 1.Table 1 Characteristics of 41 patients receiving radiation
therapy at Rigshospitalet during 2015
Data
Age, median (range), y 53 (26-79)
Tumor category, n
T1 (<20 mm) 24 (59%)
T2 (20-50 mm) 15 (37%)
T3 (>50 mm) 2 (5%)
Cancer stage, n
I 10 (24%)
II 20 (49%)
III 9 (22%)
Unknown 2 (5%)
No. of positive nodes, n
0 2 (5%)
1-3 28 (68%)
4-9 6 (15%)
>9 4 (10%)
Unknown 1 (2%)
HER2 status, n
Positive 7 (17%)
Negative 34 (83%)
ER status, n
Positive 37 (90%)
Negative 4 (10%)
Adjuvant treatment, n
None 1 (2%)
Chemotherapy* 29 (71%)
Trastuzumab 6 (15%)
Hormone therapyy 36 (88%)
No. of intercostal spaces in IMN target,z n
2 1 (2%)
3 17 (41%)
4 21 (51%)
5 2 (5%)
Abbreviations: ERZ estrogen receptor; HER2Z human epidermal
growth factor receptor 2; IMN Z internal mammary node.
* All received a combination of epirubicin, cyclophosphamide, and
docetaxel. Three patients received neoadjuvant chemotherapy.
y Nineteen patients received letrozole, and 17 received tamoxifen.
z Department guidelines recommend 3 intercostal spaces (IMN
delineated to cranial border of fourth rib). Four intercostal spaces are
recommended in cases with medial tumor location.Proton treatment planning provided more homogeneous
target coverage and sparing of dose to heart, LADCA, and
ipsilateral lung compared with the delivered photon plans
in all 41 patients. The median target coverage HI was 0.13
(range, 0.07-0.7) for photon plans and 0.05 (range, 0.04-
0.07) for protons. Figure 2A shows mean doses to delin-
eated structures with the 2 radiation treatment modalities;
despite a varying degree of underdosage of the IMN with
photon therapy, the MHD was lower with protons.
Figure 2B shows MHD and mean IMN dose. The median
MHD was 1.9 Gy (range, 0.5-7.6 Gy) with photon planning
and 0.3 Gy (range, 0.04-0.9 Gy) with proton planning. The
2 patients receiving the highest MHDs with photons, 7.6
and 6.6 Gy, respectively, were treated with the hybrid
photon technique. The median mean IMN dose was
48.5 Gy (range, 37.1-50.7 Gy) with photons and 49.7 Gy
(range, 49.0-50.1 Gy) with protons.
Bioeffect modeling
All patients had a lower EAR of at least 1 ACE at age
80 years with the proton treatment planning (Fig. 3). With
no pre-existing CRFs, the median EAR for the photon plans
was 0.5% (range, 0.03%-1.0%), and in the presence of
CRFs, it was 1.0% (range, 0.2%-2.9%). In the proton case,
the median EAR of at least 1 ACE by age 80 years was
0.06% (range, 0.004%-0.3%) and 0.13% (range, 0.02%-
0.5%) without CRFs and with CRFs, respectively. The error
bars in Figure 3 document the robustness of photon and
proton plans and suggest that photon plans were often at
least as sensitive to setup errors as proton plans. Figure A2
(available online at www.redjournal.org) presents addi-
tional information.
The estimated EARs of breast cancer recurrence after
10 years using the model based on mean dose to IMN were
essentially 0% for all proton plans and in the range of 0% to
0.9% (median, 0.10%) with photon planning (Fig. 4). A
sensitivity analysis of the effect of model assumptions is
presented in Appendix (available online at www
.redjournal.org).
Discussion
Modern photon radiation therapy lowers the MHD (14)
compared with historical cohorts. The delivered photon
plans in this study of comprehensive nodal irradiation of
left-sided breast cancer had a median MHD of 1.9 Gy,
which is lower than that in most previous reports and the
expected MHD of the RADCOMP (Radiotherapy
Comparative Effectiveness) trial comparing photon and
proton irradiation. However, although cardiac dose has
decreased over time, it is not a solved problem. Patients in
this series still had MHDs of up to 7.6 Gy. At the same
time, IMN doses were as low as 37 Gy, indicating a sub-
stantial compromise to spare the heart, which may again
cause a clinically relevant risk of recurrence (3).
Fig. 1. The photon plan delivered to a patient at Rigshospitalet in 2015 (A) and the comparative proton plan (B). Both dose
washes show the 10% to 107% dose range, and the computed tomography scan is obtained in deep inspiration breath hold.
One should note the underdosage of the internal mammary node (white arrow) in the photon plan required to comply with the
protocolized maximum dose to the heart (yellow structure). On the comparative proton plan, the internal mammary node is
adequately dosed at the same time as the heart is spared more than with photons. The light purple structure on the proton plan
is the proton-specific planning target volume.
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son with protons in a comparatively large patient series to
elucidate the distribution of potential benefit across a
population. Clearly the predicted benefit of protons will
depend on the target delineations and will likely be larger if
the IMN delineations are expanded compared with the
clinical plans (cf Table 1). Also, it should be noted that our
primary target includes only breast tissue in a tighter defi-
nition than depicted in the delineation guidelines for the50403020100
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ACE and breast cancer recurrence or death are depicted in
Figure 5, along with the results of our 41 patients. Such
risk assessments can provide clinical decision support
regarding the potential benefits of proton therapy in an
individual. It is interesting that modern proton beam spot
scanning techniques can reduce both excess risks to
essentially zero, thus eliminating the need for comparative
dose planning in the decision process. In addition, it
should be noted that the benefit from proton therapy across
the 41 patients studied here does not correlate well with
patient age (one should also refer to Fig. A3; available
online at www.redjournal.org). We, therefore, conclude
that age is an inappropriate criterion for referral of breast
cancer patients for proton therapy. Instead, we suggest that
the MHD and the amount of compromise on IMN
coverage are considered individually for each patient, aspossibly supported by Figure 5. Patients with unacceptable
heart doses or compromises to IMNs could then be
considered for proton therapy. We refrain from recom-
mending a fixed threshold given the uncertainty of the
models, but we recommend that possible cost-effectiveness
analyses in the future also consider the possible loss of
tumor control from compromising the target, rather than
cardiac dose alone (16).
A number of limitations of this study should be
acknowledged. First, the bioeffect modeling is associated
with substantial uncertainty, especially the models of risk
of recurrence. Model uncertainties and a sensitivity
analysis using another dose metric to predict risk of breast
cancer recurrence are presented in Figures A4 and A5 in
Appendix (available online at www.redjournal.org).
Clearly the results are uncertain, but our present attempt
gives a realistic scale of the issue and is, to our knowl-
edge, the first outcome data-driven model of breast cancer
recurrence resulting from target compromises. With
respect to cardiac risk estimates, there are a number of
modeling assumptions discussed in the communications
on the article by Darby et al (4). In addition, the use of
anthracycline and taxanes was infrequent in the study of
Darby et al but may possibly amplify the effect of cardiac
irradiation.
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Fig. 5. Excess absolute risk (EAR) contours of at least 1 acute coronary event (ACE) by age 80 years without (A) and with
cardiac risk factors (CRFs) (B) as a function of age at exposure (x-axis) and mean heart dose (MHD) (y-axis) from the photon
plan. (C) EAR of breast cancer recurrence (BCR) by 10 years after therapy as a function of mean dose to internal mammary
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Stick et al. International Journal of Radiation Oncology  Biology  Physics760All plans were modeled on a DIBH CT scan, which can
only be delivered in the newest proton therapy centers
and, to our knowledge, has not been introduced clinically
(17-19). Nevertheless, filling the lung with air has little
effect on cardiac dose for proton therapy (20) with en face
beam arrangement as the beam range depends predomi-
nantly on radiologic and not geometric distance (ie, the
mass of tissue in the beam path rather than the length of
the beam path). Also, our results apply to installations
with spot scanning capabilities. On the other hand, the
presented results reflect advanced photon plans in DIBH,
and centers without access to such techniques may see a
larger proportion of patients benefitting from proton
therapy referrals. Again, we recommend using the dose-
risk comparisons (eg, Fig. 5) as support for clinical de-
cisions rather than standardizing referral guidelines based
on, for example, patient age.
In conclusion, a method has been demonstrated to esti-
mate the joint risk of breast cancer recurrence and cardiac
morbidity following compromises to target coverage and
radiation exposure to the heart, respectively. Modern
photon techniques, specifically delivery in DIBH, are
associated with a low predicted risk of cardiotoxicity;
however, a subset of patients may still have a relevant
benefit from referral to proton therapy. Joint estimation of
breast cancer recurrence and cardiac morbidity risk should
be considered as an integral component of clinical decision
support and for shared decision making with prospective
patients, albeit with acknowledgment of the uncertainties of
the modeling.References
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